PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2017 | 4 | 4 | 218-222
Article title

Metody leczenia cukrzycowego obrzęku plamki

Content
Title variants
EN
Current treatment of diabetic macular edema
Languages of publication
PL
Abstracts
EN
Diabetic macular edema is one of the most serious ocular complications in diabetes. At present, several forms of therapy are available that are used depending on the severity of the lesions, the risk of complications, compliance and the availability. The anti-VEGF drugs have become the standard of choice and there are available three types: ranibizumab, aflibercept, and bevacizumab. The highest efficiency was proven in aflibercept. Other treatments include conventional lasers, steroid injections, subthreshold micropulse laser therapy and combinations of the above methods. It is important to cooperate with a diabetologist and encourage the patient to control levels of glycated hemoglobin, blood pressure, and lipid profile.
PL
Cukrzycowy obrzęk plamki to jedno z najpoważniejszych powikłań okulistycznych cukrzycy. Obecnie dostępnych jest kilka form terapii, które stosuje się w zależności od stopnia zaawansowania zmian, ryzyka powikłań, możliwości współpracy z pacjentem i dostępności leczenia. Złotym standardem stały się iniekcje doszklistkowe preparatów anty-VEGF: ranibizumabu, afliberceptu i bewacyzumabu. Najwyższą skutecznością w badaniach odznaczał się aflibercept. Pozostałe rodzaje leczenia to: laserokoagulacja w trybie ciągłym, iniekcje doszklistkowe preparatów steroidowych, laseroterapia w trybie mikropulsowym, kombinacje powyższych metod oraz leczenie chirurgiczne. Bardzo istotna jest współpraca lekarza diabetologa z pacjentem, a zwłaszcza zachęcanie chorego do utrzymywania prawidłowego stężenia hemoglobiny glikowanej oraz prawidłowych wartości ciśnienia tętniczego i parametrów lipidogramu.
Discipline
Publisher

Journal
Year
Volume
4
Issue
4
Pages
218-222
Physical description
Contributors
  • Wojewódzki Szpital Okulistyczny w Krakowie
  • Wojewódzki Szpital Okulistyczny w Krakowie
  • Wojewódzki Szpital Okulistyczny w Krakowie
References
  • 1. White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010; 59: 1244-1253.
  • 2. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16.
  • 3. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol 1985; 103: 1796-1806.
  • 4. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, doublemasked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
  • 5. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
  • 6. Nguyen QD, Brown DM, Marcus DM, et al. RISE and RIDE Research Group: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.
  • 7. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972-979.
  • 8. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 2016; 123: 2376-2385.
  • 9. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the DAVINCI study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012; 119: 1658-1665.
  • 10. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372(13): 1193-1203.
  • 11. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117(6): 1064-1077.e35.
  • 12. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128(3): 289-296.
  • 13. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 2014; 121(12): 2473-2481.
  • 14. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 119: 2125-2132.
  • 15. Nakamura Y, Mitamura Y, Ogata K, et al. Functional and morphological changes of macula after subthreshold micropulse diode laser photocoagulation for diabetic macular oedema. Eye (Lond) 2010; 24(5): 784-788.
  • 16. Chen G, Tzekov R, Li W, et al. Subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: A Meta-Analysis of Randomized Controlled Trials. Retina (Philadelphia, Pa) 2016; 36(11): 2059-2065.
  • 17. Laursen ML, Moeller F, Sander B, et al. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004; 88(9): 1173-1179.
  • 18. Sivaprasad S, Sandhu R, Tandon A, et al. Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clin Exp Ophthalmol 2007; 35(7): 640-644.
  • 19. Mansouri A, Sampat KM, Malik KJ, et al. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye (Lond) 2014; 28(12): 1418-1424.
  • 20. Callanan D, Gupta S, Boyer D, et al. Ozurdex PLACID Study Group: Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013; 120: 1843-1851.
  • 21. Mehta H, Gillies MC, Fraser-Bell S. Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review. Clin Experiment Ophthalmol 2016; 44(4): 335-339.
  • 22. Elhamid AHA. Combined Intravitreal Dexamethasone Implant And Micropulse Yellow Laser For Treatment Of Anti-VEGF Resistant Diabetic Macular Edema. Open Ophthalmol J 2017; 11: 164-172.
  • 23. Berrocal MH, Acaba LA, Acaba A. Surgery for Diabetic Eye Complications. Curr Diab Rep 2016; 16(10): 99.
  • 24. Haller JA, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117(6): 1087-1093.e3.
  • 25. Gale R, Scanlon PH, Evans M, et al. Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease. Eye 2017; 31(Suppl 1): S1-S20. DOI: 10.1038/eye.2017.53.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-9c635661-6149-4330-b4f9-39a18a6c9a11
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.